Regeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells 400 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $900.00, for a total value of $360,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $542,700. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Wednesday, September 2nd, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $850.00, for a total value of $340,000.00.
• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Trading Up 1.3%

NASDAQ:REGN opened at $973.36 on Wednesday. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $798.74 and its two-hundred day moving average is $740.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $975.49. The company has a market cap of $100.22 billion, a PE ratio of 21.49, a P/E/G ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same quarter last year, the firm earned $11.83 EPS. The business’s revenue was up 36.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Wall Street Analyst Weigh In

Several research firms have weighed in on REGN. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a research report on Friday, October 30th. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Finally, Truist Financial boosted their price objective on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $898.97.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. LCM Capital Management Inc boosted its position in Regeneron Pharmaceuticals by 2.2% during the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock worth $467,000 after acquiring an additional 13 shares during the period. Arjuna Capital grew its stake in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares in the last quarter. Oakworth Capital Inc. grew its stake in Regeneron Pharmaceuticals by 25.0% during the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 14 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after acquiring an additional 15 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported third-quarter revenue of $5.12 billion, up 36.3% year over year and ahead of estimates, while earnings of $20.07 per share also topped consensus. Analysts pointed to strength in commercial products and progress in the pipeline as signs of underlying business health. REGN Q3 deep dive: pipeline progress and core brands drive outperformance
• Positive Sentiment: Following the results, multiple firms raised their price targets; some maintained Buy or Overweight ratings, and forecasts cited in coverage reached as high as $1,175. These revisions reflect improved expectations after the earnings beat. Analysts raise forecasts after upbeat Q3 results
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares under a pre-arranged Rule 10b5-1 trading plan. The planned nature of the sale may reduce its significance as a signal about the company’s outlook. SEC filing
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, with a 0.4% indicated yield. Management also scheduled appearances at upcoming healthcare investor conferences; neither announcement provides a major near-term earnings catalyst. Investor conference presentations
• Negative Sentiment: Despite raising targets, several firms—including RBC, Morgan Stanley, Bernstein and Wells Fargo—kept neutral-style ratings and set targets below the recent share price, signaling valuation caution after the stock’s rally. RBC comments on Regeneron’s Q3 results

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.